Novartis (NVS) Q2 2026 Earnings: Core EPS Beats Estimates on +3% Sales Growth
Key Takeaways
- Novartis reported Q2 2026 net sales of $14.4 billion, up 3% year-over-year in USD terms.
- Core earnings per share came in at $2.41, slightly below the prior year but ahead of analyst consensus estimates around $2.16–$2.17.
- Reported net income declined to $3.3 billion from $4.0 billion a year earlier due to one-time factors.
- Core operating income remained essentially flat year-over-year at $5.9 billion.
- Free cash flow totaled $5.6 billion, down from $6.3 billion in the prior-year quarter.
- Shares reacted positively in after-hours trading following the better-than-expected core results.
Why These Results Matter for Investors
Novartis, a leading global pharmaceutical company, delivers quarterly results that provide investors with critical updates on its innovative medicines portfolio, including key growth drivers in oncology, cardiology, and neuroscience. The Q2 2026 report arrives amid steady demand for its flagship products and ongoing pipeline advancements. Earnings season for healthcare firms like Novartis often influences broader sector sentiment, as results can signal trends in drug pricing, regulatory approvals, and competitive dynamics. Strong or weak performance here can affect investor confidence in the company’s ability to sustain long-term growth in a high-stakes industry.
Q2 2026 Financial Results Breakdown
Novartis announced its Q2 2026 financial results on July 21, 2026. Net sales reached $14.408 billion, representing a 3% increase from $14.054 billion in Q2 2025 (1% growth in constant currencies). Core operating income held steady at $5.94 billion. Core net income was $4.578 billion, and core earnings per share (EPS) came in at $2.41, essentially flat year-over-year on a constant-currency basis. Reported net income fell 19% to $3.257 billion, with reported EPS at $1.71, reflecting the impact of certain non-core items. The company’s core EPS exceeded consensus analyst estimates of approximately $2.16–$2.17. Revenue also topped expectations near $14.12 billion. Operating income and free cash flow showed modest declines compared with the prior year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Following the July 21 release, Novartis shares rose in after-hours trading as investors focused on the earnings beat and resilient core performance. The positive reaction reflected relief that core metrics met or exceeded expectations despite a reported net income decline driven by non-recurring items. Broader market sentiment toward the healthcare sector remained constructive, with analysts highlighting the company’s ability to maintain core profitability amid evolving industry conditions.
Forward Outlook and Key Factors to Monitor
Investors will next focus on Novartis’ full-year guidance and any updates provided during the earnings call. Key areas to watch include the performance of leading products in oncology and other therapeutic areas, as well as progress on the company’s research and development pipeline.
Cost management, currency fluctuations, and potential regulatory or competitive developments in key markets could influence results in coming quarters. Margin trends and free cash flow generation will also remain important indicators of operational efficiency.
Upcoming catalysts such as new product launches, clinical trial readouts, or strategic partnerships may shape the outlook. Broader industry dynamics, including healthcare policy changes and pricing pressures, warrant continued attention as the company navigates the second half of the year. From what I see, monitoring these elements closely will be important for understanding the sustainability of the core performance.
My Experience with Tickeron’s AI Tools
In my own research process, I often turn to Tickeron’s AI Screener for deeper market scans. This AI-powered stock and ETF discovery tool helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NVS's RSI Oscillator ascending out of oversold territory
The RSI Indicator for NVS moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 14 of the 24 cases the stock moved higher. This puts the odds of a move higher at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 54 cases where NVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Moving Average Convergence Divergence (MACD) for NVS just turned positive on September 24, 2026. Looking at past instances where NVS's MACD turned positive, the stock continued to rise in 26 of 46 cases over the following month. The odds of a continued upward trend are 57%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in 182 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVS as a result. In 42 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.
NVS moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVS crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 6 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 38%.
The 50-day moving average for NVS moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
NVS broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.720) is normal, around the industry mean (19.199). P/E Ratio (22.187) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (3.441) is also within normal values, averaging (5.738). Dividend Yield (0.032) settles around the average of (0.025) among similar stocks. P/S Ratio (4.715) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement